在年轻和中年成人中抑制控制和心脏反应性
Cédric T Albinet1, Benoît Valéry1, Mickael Causse2
1Laboratoire Sciences de la Cognition, Technologie, Ergonomie (SCoTE), Université de Toulouse, INU Champollion, Albi, France.
Biological psychology
|October 18, 2025
概括
心脏反应率,以排泄前期 (PEP) 的变化来衡量,随着时间的推移和认知任务中的任务重复习惯. 这种心脏反应模式在年轻人和中年成人中都被观察到.
科学领域:
- 心血管生理学心血管生理学
- 认知神经科学 认知神经科学
- 心理生理学 心理生理学
背景情况:
- 心脏反应,特别是排泄前期 (PEP) 变化,是认知挑战期间自主神经系统活动的敏感指标.
- 了解PEP动态如何随着认知负载,任务重复和年龄而变化,对于阐明认知努力和心血管调节之间的相互作用至关重要.
研究的目的:
- 在年轻和中年成人中,调查需要抑制控制的认知任务期间心脏反应 (PEP) 的时间动态.
- 检查PEP反应性如何随着认知负载,任务持续时间和重复任务暴露而变化.
- 评估认知表现和心脏反应的年龄相关差异.
主要方法:
- 参与者:28名年轻成年人 (18-27岁) 和22名中年人 (55-65岁).
- 任务:侧面任务的变化,包括中性,一致,不一致和No-Go试验.
- 测量:包括心率,血压和排泄前期 (PEP) 在内的心血管参数被连续记录.
主要成果:
- PEP反应性表现出一种短暂的性质,在任务执行的最初一分钟内以及在重复任务中减少,这表明习惯.
- PEP反应性与认知负载相关,但与认知表现不一致.
- 虽然在认知表现和休息/任务PEP方面发现了年龄差异,但PEP反应性在各年龄组之间没有显著差异.
结论:
- 心脏反应 (PEP) 表现出习惯性和敏感性特征,受认知负载和任务重复的影响,与双过程习惯性理论保持一致.
- PEP反应性似乎是一个强大的衡量标准,不像休息心血管参数或认知表现那样受到年龄的影响.
- 这些发现有助于理解基于努力的心血管反应及其在整个生命周期的认知需求的调制.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Regulation of Heart Rates
3.7K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
3.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antihypertensive Drugs: Types of β-Blockers
1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K


